Mergers and acquisitions have been highlighted as key drivers of growth for pharma companies in China as domestic companies look to expand globally and multinationals attempt to localize.

The change of seasons coincides with a flurry of key personnel moves in the Asian pharmaceutical scene. Xian Janssen China President Thad Huston moves up, Simcere vice president Jie Liu D’Elia joins BMS. Personnel changes also took place in Takeda, Lupin, inVentive Health and the Japan Pharmaceutical Manufacturers Association.

Nanjing Pharma has seen three top executive departures in recent months, which could impact its collaboration with U.K. pharmacy giant Alliance Boots. Meanwhile, personnel changes also took place at BIO, Mundipharma, Beigene, Catalent Pharma Solutions and Zhejiang FDA.

Nanjing Pharma has seen three top executive departures in recent months, which could impact its collaboration with U.K. pharmacy giant Alliance Boots. Meanwhile, personnel changes also took place at BIO, Mundipharma, Beigene, Catalent Pharma Solutions and Zhejiang FDA.